Results 41 to 50 of about 16,120 (219)
Left Bundle Branch Pacing in Transthyretin Cardiac Amyloidosis and Alternating Bundle Branch Block
Progressive conduction system disease affects patients with transthyretin cardiac amyloidosis, often requiring permanent pacing as the His-Purkinje system is affected. We present a case of left bundle branch pacing in a patient with transthyretin cardiac
Taha Ahmed, MD +5 more
doaj +1 more source
CRISPR/Cas9 has revolutionized the field of gene therapy, but delivery remains an outstanding issue. We propose a nonviral gold‐nanoparticle platform for co‐delivery of CRISPR/Cas9 ribonucleoprotein and long 2.1 kilobase dsDNA transgene constructs. This CRISPR‐AuNP is inexpensive to produce and mediate gene editing and DNA delivery in T cells and CD34+
Rachel A. Cunningham +8 more
wiley +1 more source
Misdiagnosis of hereditary amyloidosis as AL (Primary) amyloidosis [PDF]
Background: Hereditary, autosomal dominant amyloidosis, caused by mutations in the genes encoding transthyretin, fibrinogen A -chain, lysozyme, or apolipoprotein A-I, is thought to be extremely rare and is not routinely included in the differential ...
Booth, D.R. +7 more
core
Oligonucleotide Drugs for Transthyretin Amyloidosis [PDF]
In this issue of the Journal, Adams et al.1 and Benson et al.2 report the results of two randomized, double-blind, controlled trials testing the therapeutic efficacy of two different chemically mod...
Adams, D, Hawkins, PN, Polydefkis, M
openaire +6 more sources
Decoding RNA regulation: Challenges and opportunities for RNA‐based therapies in Europe
Abstract RNA‐based medicinal products represent a promising frontier in personalised medicine, offering sequence‐specific disease targeting at various molecular levels, yet their clinical translation in the European Union (EU) may be hindered by regulatory uncertainty around definitions and evidence requirements; this study therefore aims to identify ...
Olivia C. Lewis +4 more
wiley +1 more source
Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis [PDF]
Background: Amyloid transthyretin (ATTR) amyloidosis is caused by the systemic deposition of transthyretin molecules, either normal (wild-type ATTR, ATTRwt) or mutated (variant ATTR, ATTRv). ATTR amyloidosis is a disease with a severe impact on patients’
Cappelli F. +20 more
core +1 more source
Wild-type transthyretin amyloidosis is a disease characterized by deposition of transthyretin amyloid protein in systemic organs and tissues, especially the heart, lungs, tenosynovium, and ligaments.
Koji Takahashi, MD, PhD +8 more
doaj +1 more source
ABSTRACT Aortic stenosis (AS) is associated with a heightened burden of cardiovascular comorbidities, atrial fibrillation (AF), and progressive valvular calcification, all of which may contribute to cerebrovascular events across the disease continuum.
Priyanka Boettger +7 more
wiley +1 more source
Transthyretin (TTR) amyloidosis causes heart failure from cardiac deposition of TTR amyloid fibrils, the by-product of TTR homotetramer disassembly. Wild-type (WT) TTR deposition leads to senile amyloidosis, predominantly manifesting with cardiomyopathy.
Daniel P. Judge +2 more
core +1 more source
Summary: Amyloidogenic transthyretin (ATTR) amyloidosis is a relentlessly progressive disease caused by the misfolding and systemic accumulation of amyloidogenic transthyretin into amyloid fibrils.
Rose Pedretti, BS +7 more
doaj +1 more source

